JUNOMINE ER phentermine (as hydrochloride) 40 mg extended release tablet blister pack

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

phentermine hydrochloride, Quantity: 49.7 mg

Available from:

Juno PC Holdings Pty Limited

Pharmaceutical form:

Tablet, modified release

Composition:

Excipient Ingredients: cetostearyl alcohol; sorbitol; maltodextrin; stearic acid; magnesium stearate; titanium dioxide; sunset yellow FCF aluminium lake; purified talc; polyvinyl alcohol; macrogol 3350; brilliant scarlet 4R aluminium lake

Administration route:

Oral

Units in package:

30, 90

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

Phentermine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (BMI) of 30 kg/m2 or greater.,The treatment with Phentermine can be initiated in overweight patients with a lower BMI (25 to 29.9 kg/m2), which increases the risk of morbidity from a number of disorders. Secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

Product summary:

Visual Identification: Phentermine ER 40 mg tablets are orange film coated capsule shaped tablets; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Authorization status:

Registered

Authorization date:

2020-01-09